Dendritic cell-based vaccine: a promising approach for cancer immunotherapy

Article metrics

Abstract

The unique ability of dendritic cells to pick up antigens and to activate naive and memory CD4+ and CD8+ T cells raised the possibility of using them to trigger a specific anti-tumor immunity. If numerous studies have shown a major interest in dendritic cell-based vaccines for cancer immunotherapy in animal models, only a few have been carried out in human cancers. In this review, we describe recent findings in the biology of dendritic cells that are important to generate anti-tumor cytotoxic T cells in vitro and we also detail clinical studies reporting the obtention of specific immunity to human cancers in vivo using reinfusion of dendritic cells pulsed with tumor antigens.

Author information

Correspondence to B Klein.

Rights and permissions

Reprints and Permissions

About this article

Keywords

  • dendritic cells
  • cancer
  • immunotherapy

Further reading